Treatment with Brilacidin by daily enema administration is performed consecutively for 42 days.
“We remain extremely encouraged by the results that continue to emerge from this trial. In addition, the clinical sites at which the study is being performed are now even more enthusiastic about recruiting additional patients to the trial. Such enthusiasm is a good indicator of Brilacidin’s potential in treating ulcerative colitis and other inflammatory bowel diseases. We look forward to seeing data from the next cohorts,” said Arthur P. Bertolino, MD, PhD, MBA, Cellceutix President and Chief Medical Officer.